Anti-obesity composition
By using oral dosage form compositions of naltrexone and phentermine hydrochloride in the treatment of obesity, combined with pharmaceutical excipients, the problem of insufficient effectiveness and compliance of existing obesity drugs was solved, and significant Weight loss effects and safety.
Patent Information
- Application Number
- CN202380028246.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-18
- Filing Date
- 2023-03-07
- Publication Date
- 2024-11-08
AI Technical Summary
The existing obesity drugs are insufficiently effective and the patient's compliance is poor, making it difficult to effectively treat obesity.
Provided an oral dosage form composition comprising a therapeutically effective amount of naltrexone and phentermine hydrochloride, and a pharmaceutically acceptable excipient for inducing weight loss and prescribed by a health care provider and patient Apply on your own to improve compliance.
The effectiveness and safety of obesity treatment was significantly improved, and the patient's compliance with weight loss recommendations was increased. Patients lost 4.6% to 13.4% after using the composition, and no serious side effects occurred.
Abstract
Description
[0001] CROSS REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 63 / 321,533, filed on March 18, 2022, the contents of which are incorporated herein by reference. Background Art
[0003] Obesity is a medical problem that is primarily caused by overeating the wrong foods. Currently used obesity medications are only marginally effective. Furthermore, healthcare providers' recommendations for such medications are met with inadequate and / or inconsistent patient compliance (adherence to the prescribed regimen). There is a need for obesity medications and methods of using the same. Summary of the invention
[0004] One aspect provides a dosage composition for oral administration to a subject in need of treatment for obesity, the dosage composition comprising, consisting of, or consisting essentially of a therapeutically effective amount of naltrexone, a therapeutically effective amount of phentermine, and one or more pharmaceutically acceptable excipients.
[0005] One aspect provides a dosage composition for oral administration to a subject in need of treatment for obesity, the dosage composition comprising, consisting of, or consisting essentially of a therapeutically effective amount of naltrexone hydrochloride, a therapeutically effective amount of phentermine hydrochloride, and one or more pharmaceutically acceptable excipients.
[0006] One aspect provides a method for inducing weight loss in a subject in need of weight loss, the method comprising administering to the subject a dosage composition comprising, consisting of, or consisting essentially of a therapeutically effective amount of naltrexone hydrochloride, a therapeutically effective amount of phentermine hydrochloride, and one or more pharmaceutically acceptable excipients.
[0007] One aspect provides a method for inducing compliance with a healthcare provider's weight loss recommendations in a patient in need of weight loss, the method comprising the healthcare provider prescribing to the patient a dosage composition comprising, consisting of, or consisting essentially of a therapeutically effective amount of naltrexone hydrochloride, a therapeutically effective amount of phentermine hydrochloride, and one or more pharmaceutically acceptable excipients; and the patient self-administering the dosage composition for a period of time, at the end of which the patient has experienced weight loss, thereby complying with the healthcare provider's recommendations. DETAILED DESCRIPTION
[0008] In order to solve the problem of obesity, the present disclosure provides a novel obesity drug with enhanced effectiveness, safety and economy. The drug controls hunger, appetite and craving, promotes satiety, and satisfies patient compliance.
[0009] In one embodiment, a dosage form composition is provided, comprising a therapeutically effective amount of naltrexone and a therapeutically effective amount of phentermine and one or more pharmaceutically acceptable excipients.
[0010] One aspect provides a dosage composition for oral administration to a subject in need of treatment for obesity, the dosage composition comprising a therapeutically effective amount of naltrexone hydrochloride, a therapeutically effective amount of phentermine hydrochloride, and one or more pharmaceutically acceptable excipients.
[0011] In certain embodiments, the therapeutically effective amount of naltrexone is about 1.5 to about 4.5 mg or any value therebetween. In certain embodiments, the therapeutically effective amount of naltrexone is 1.5, 3.0, or 4.5 mg. In one embodiment, the therapeutically effective amount of phentermine is about 15 to about 37.5 mg or any value therebetween. In certain embodiments, the therapeutically effective amount of phentermine is 15, 30, or 37.5 mg. In certain embodiments, the dosage form is in the form of a capsule.
[0012] One aspect provides a method for inducing weight loss in a subject in need thereof, the method comprising administering to the subject a dosage composition comprising a therapeutically effective amount of naltrexone hydrochloride, a therapeutically effective amount of phentermine hydrochloride, and one or more pharmaceutically acceptable excipients.
[0013] In one embodiment, a method for treating a subject in need of treatment for obesity is provided, the method comprising administering to the subject a therapeutically effective amount of a composition comprising naltrexone, phentermine, and one or more pharmaceutically acceptable excipients.
[0014] In certain embodiments, administration is performed once a day. In one embodiment, administration is performed twice a day. In one embodiment, administration is oral.
[0015] As used in this specification and claims, "naltrexone" may refer to 20 H 23 NO4 and naltrexone base with CAS No. 16590-41-3, or C 20 H 23 NO4.HCl and naltrexone hydrochloride with CAS number 16676-29-2, as specified in the context and in the use in the pharmaceutical and medical fields.
[0016] As used in this specification and claims, "naltrexone hydrochloride" refers to 20 H 23 NO4.HCl and naltrexone hydrochloride with CAS number 16676-29-2.
[0017] As used in this specification and claims, "phentermine" may refer to a compound of formula C 10 H 15 N and CAS No. 122-09-8, or phentermine base with molecular formula C 10 H 15 N.HCl and phentermine hydrochloride with CAS number 1197-21-3, as specified in the context and in the use in the pharmaceutical and medical fields.
[0018] As used in this specification and claims, "phentermine hydrochloride" refers to the 10 H 15 N.HCl and phentermine hydrochloride with CAS number 1197-21-3.
[0019] In one example, a composition comprising a therapeutically effective amount of naltrexone and a therapeutically effective amount of phentermine and one or more pharmaceutically acceptable excipients is prepared. The starting materials include the following (per 100 size 1 capsules): Avicel PH105 (microcrystalline cellulose), from Letco Medical, 23.976 g; phentermine hydrochloride USP, from Medisc, 1.5 g; naltrexone hydrochloride USP, from Letco Medical, 0.15 g; blue food coloring, from Letco Medical, 0.024 g; size 1 capsules, from Letco Medical. Mixing is performed as follows: first add Avicel PH105 to the mortar, then add phentermine and naltrexone, and finally add blue food coloring to help confirm proper mixing; use a pestle to reduce the particle size, and evenly mix the active ingredients and excipients to prepare a powder. The capsule filling is carried out as follows: using the ProFiller equipment; the empty capsules are placed in the ProFiller and separated; the powder is then dispersed into the opened capsules and compacted repeatedly using a pin-tamper until no powder is visible on the ProFiller platform; the capsules are closed and secured using the machine. Packaging is carried out as follows: each batch is given a batch number and stored in the original plastic container from the empty capsule wholesaler at controlled room temperature and humidity with an appropriate expiration date of 180 days. Distribution is carried out as follows: the capsules are distributed like any other commercially available capsules that can be distributed in a pharmacy environment - on a prescription order and in plastic vials with appropriate labels and child-resistant caps.
[0020] The compounding (or manufacturing) described in the preceding paragraph may be modified to accommodate various masses and ratios of phentermine and naltrexone. Other pharmaceutically acceptable excipients may be substituted for the excipients described in the preceding paragraph, or more generally, other combinations of excipients may be used in the compounding or manufacturing.
[0021] In one example, each of a series of patients was prescribed a filled capsule made as described above, containing phentermine 15 mg / naltrexone 1.5 mg, once a day for 7-10 days (for tolerance), then twice a day. Typically, patients self-administered this prescription medication (filled capsules) 1-2 hours before each lunch and dinner. Another series of patients self-administered two such filled capsules together every morning. Another series of patients self-administered one such filled capsule per day, usually in the morning. Another series of patients self-administered one such filled capsule per day before dinner. Another series of patients was prescribed a filled capsule made as described above, but containing 37.5 mg phentermine and 3 mg naltrexone (per capsule), self-administered once a day. Each series of patients experienced meaningful weight loss. No serious adverse events were observed. Unexpectedly, each series of patients adhered to the prescribed regimen and noticed increased energy, a tendency to make healthier dietary choices and consume less food, and significantly reduced hunger, cravings, and appetite.
[0022] Representative weight loss results experienced by patients who were prescribed and self-administered the medications disclosed herein (comprising naltrexone and phentermine) are as follows, where "n" refers to the number of patients (it should be noted that this is a "snapshot" of the patients' weight loss after a given period of time, rather than a longitudinal study of the same patients over time): 4.6% weight loss after one month (n=14); 6.35% weight loss after two months (n=17); 7.52% weight loss after three months (n=10); 13.4% weight loss after four months (n=1); 8.2% weight loss after five months (n=2).
[0023] Those skilled in the art will recognize that a significant medical problem has been solved by the subject matter of the present disclosure. The doses of naltrexone and phentermine are selected to maximize effectiveness and minimize side effects and "bad" symptoms, thereby maximizing compliance and overall tolerability. Each of naltrexone and phentermine undergoes hepatic metabolism and renal excretion. The standard recommendation for duration of use may be 3 months, or up to 6 or 9 months if effective, but longer term use may be recommended if continued effectiveness is demonstrated in addition to the favorable safety profile observed.
[0024] According to the presently disclosed subject matter, it is contemplated that a patient may self-administer a total of about 1.5 to about 4.5 mg of naltrexone and about 15 to about 37.5 mg of phentermine per day. Such administration may be once per day, or such administration may be divided into two times per day.
[0025] As used in this specification and claims, the singular includes plural referents unless the context clearly dictates otherwise. When used in this specification and claims as an adverb rather than a preposition, "about" means "approximately" and includes the stated value and every non-negative value within 10% of that value; in other words, "about 100%" includes 90% and 110% and every value therebetween. Unless otherwise specified, every range or interval includes the endpoints and every value therebetween.
[0026] As used herein, the term "consisting essentially of" is defined to mean that the specified materials may optionally be included in the composition without materially affecting the basic and novel characteristics of the claim. Examples of such materials include preservatives and dispersants that have no effect on the function of the therapeutic composition.
[0027] Assay methods for the active pharmaceutical ingredients disclosed herein are described, inter alia, in the most recent edition of the United States Pharmacopoeia, which is incorporated herein by reference.
[0028] The pharmaceutically acceptable excipients disclosed herein are described, inter alia, in the most recent edition of the Handbook of Pharmaceutical Excipients published by the American Pharmacists Association, which is incorporated herein by reference.
[0029] After mixing or manufacturing, the dosage form compositions disclosed herein can be placed in suitable container closure systems known in the art. Methods for filling such container closure systems are known in the art.
[0030] With the benefit of the teachings presented in the foregoing description, those skilled in the art to which the present disclosure belongs will think of many modifications and other embodiments of the present disclosure. It should therefore be understood that the scope of what has been conceived and put into practice is not limited to the specific embodiments disclosed herein, and modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are used herein, they are used only in a general and descriptive sense, and not for the purpose of limitation.
Claims
1. A dosage form composition for oral administration to a subject in need of treatment for obesity, the dosage form composition comprising a therapeutically effective amount of naltrexone, a therapeutically effective amount of phentermine and one or more pharmaceutically acceptable excipients.
2. The dosage form composition of claim 1, wherein the therapeutically effective amount of naltrexone is from about 1.5 to about 4.5 mg.
3. The dosage composition according to claim 2, wherein the therapeutically effective amount of naltrexone is 1.5, 3.0 or 4.5 mg.
4. The dosage form composition according to claim 1, wherein the therapeutically effective amount of phentermine is from about 15 to about 37.5 mg.
5. The dosage composition according to claim 4, wherein the therapeutically effective amount of phentermine is 15, 30 or 37.5 mg. The dosage composition according to claim 1 , which is in the form of a capsule.
7. A dosage composition for oral administration to a subject in need of treatment for obesity, the dosage composition comprising a therapeutically effective amount of naltrexone hydrochloride, a therapeutically effective amount of phentermine hydrochloride, and one or more pharmaceutically acceptable excipients.
8. The dosage form composition of claim 7, wherein the therapeutically effective amount of naltrexone hydrochloride is from about 1.5 to about 4.5 mg.
9. The dosage composition according to claim 8, wherein the therapeutically effective amount of naltrexone hydrochloride is 1.5, 3.0 or 4.5 mg.
10. The dosage form composition of claim 7, wherein the therapeutically effective amount of phentermine hydrochloride is from about 15 to about 37.5 mg.
11. The dosage composition according to claim 10, wherein the therapeutically effective amount of phentermine hydrochloride is 15, 30 or 37.5 mg.
12. The dosage composition according to claim 7, which is in the form of a capsule.
13. A method for inducing weight loss in a subject in need of weight loss, the method comprising administering to the subject a dosage composition comprising a therapeutically effective amount of naltrexone hydrochloride, a therapeutically effective amount of phentermine hydrochloride, and one or more pharmaceutically acceptable excipients.
14. The method of claim 13, wherein the administration is performed once a day.
15. The method of claim 13, wherein the administration is performed twice daily.
16. The method of claim 13, wherein the therapeutically effective amount of naltrexone hydrochloride is from about 1.5 to about 4.5 mg.
17. The method of claim 16, wherein the therapeutically effective amount of naltrexone hydrochloride is 1.5, 3.0 or 4.5 mg.
18. The method of claim 13, wherein the therapeutically effective amount of phentermine hydrochloride is from about 15 to about 37.5 mg.
19. The method of claim 18, wherein the therapeutically effective amount of phentermine hydrochloride is 15, 30 or 37.5 mg.
20. The method of claim 13, wherein the dosage composition is in the form of a capsule.
21. A method for inducing compliance with a healthcare provider's weight loss recommendations in a patient in need of weight loss, the method comprising the healthcare provider prescribing to the patient a dosage composition comprising a therapeutically effective amount of naltrexone hydrochloride, a therapeutically effective amount of phentermine hydrochloride, and one or more pharmaceutically acceptable excipients; and the patient self-administering the dosage composition over a period of time, at the end of which the patient has experienced weight loss, thereby complying with the healthcare provider's recommendations.
22. The method of claim 21, wherein the self-administration is performed once a day.
23. The method of claim 21, wherein the self-administration is performed twice daily.
24. The method of claim 21, wherein the therapeutically effective amount of naltrexone hydrochloride is from about 1.5 to about 4.5 mg.
25. The method of claim 24, wherein the therapeutically effective amount of naltrexone hydrochloride is 1.5, 3.0 or 4.5 mg.
26. The method of claim 21, wherein the therapeutically effective amount of phentermine hydrochloride is from about 15 to about 37.5 mg.
27. The method of claim 26, wherein the therapeutically effective amount of phentermine hydrochloride is 15, 30 or 37.5 mg.
28. The method of claim 21, wherein the dosage composition is in the form of a capsule.
